Colossal Biosciences has expanded its Series C funding round with an additional $120 million, bringing total raised to over $555 million since inception. The Dallas-based company focuses on reviving extinct animals, including the woolly mammoth and recently the dodo bird. Advances include successful growth of pigeon primordial germ cells—the first step toward generating dodos—and engineered gene-edited chickens to function as surrogates. The company also created the Mauritius Dodo Advisory Committee to guide ecological rewilding efforts. The funding aims to accelerate conservation and genetic engineering initiatives.